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Background: The objective of this study was to develop pegylated poly lactide-co-glycolide acid 
(PLGA) immunonanocarriers for targeting delivery of docetaxel to human breast cancer cells.
Methods: The polyethylene glycol (PEG) groups on the surface of the PLGA nanoparticles 
were functionalized using maleimide groups. Trastuzumab, a monoclonal antibody against 
human epidermal growth factor receptor 2 (HER2) antigens of cancer cells, used as the targeting 
moiety, was attached to the maleimide groups on the surface of pegylated PLGA nanoparticles. 
Nanoparticles prepared by a nanoprecipitation method were characterized for their size, size dis-
tribution, surface charge, surface morphology, drug-loading, and in vitro drug release profile.
Results: The average size of the trastuzumab-decorated nanoparticles was 254 ± 16.4 nm and 
their zeta potential was −11.5 ± 1.4 mV . The average size of the nontargeted PLGA nanopar-
ticles was 183 ± 22 nm and their zeta potential was −2.6 ± 0.34 mV . The cellular uptake of 
nanoparticles was studied using both HER2-positive (SKBR3 and BT-474) and HER2-negative 
(Calu-6) cell lines.
Conclusion: The cytotoxicity of the immunonanocarriers against HER2-positive cell lines was 
significantly higher than that of nontargeted PLGA nanoparticles and free docetaxel.
Keywords: nanoparticles, drug targeting, immunonanocarriers, trastuzumab, docetaxel, PLGA, 
HER2 receptor
Introduction
An important goal of chemotherapy is minimizing dose-dependent side effects 
because of nonspecific biodistribution of chemotherapeutic agents. Many nano-
particulate drug delivery systems have been designed to deliver chemotherapy 
agents to the site of interest, minimize side effects, and improve the efficacy of 
anticancer agents, and to enhance biocompatibility, serum stability, and the in 
vivo drug delivery profile.1 Improved drug selectivity, capability to carry a high 
concentration of drug to target sites, protection of drugs from enzymatic attack, 
and the possibility to use a similar carrier to encapsulate various drugs with no 
covalent conjugation to therapeutic agents, are some of the advantages of nano-
particles.2 The surface modification of nanoparticles with peptides, nucleic acids, 
antibodies, aptamers, or small molecules that bind to antigens on the surface of 
cells or tissues may be considered for targeted delivery of drugs to tumor cells or 
malignant tissue.3International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Among the targeting moieties, monoclonal antibodies 
have been those used most often for the targeting of nano-
particles to tumor sites. Similar to metastatic tumors, primary 
tumors usually overexpress antigens on their surfaces (such 
as epidermal growth factor receptor in lymphoma cancer and 
human epidermal growth factor receptor 2 (HER2) in breast 
cancer). Therefore, monoclonal antibodies specific to certain 
antigens on the surface of cancer cells may be considered as 
targeting moieties against tumors.4 The HER2 receptor, over-
expressed in about 20%–25% of breast cancers, is one of the 
major targets for the design of anticancer drugs. Trastuzumab 
(Herceptin®), a monoclonal antibody against HER2-positive 
cells, is licensed by the US Food and Drug Administration.5 
HER2 is a transmembrane receptor that is readily accessible 
to antibody-based therapy. These receptors are internalized 
by receptor-mediated endocytosis. This is beneficial when 
the purpose is active targeting. Certainly, this characteristic 
promotes intracellular accumulation of anti-HER2-covered 
immunonanocarriers, including anticancer drugs.2
Poly lactide-co-glycolide (PLGA), from the polyester fam-
ily of biodegradable polymers used frequently as controlled 
drug delivery systems, has been used by many researchers 
for passive and active targeting of anticancer agents.6 This 
polymer has been widely used in biomedical manufacturing 
because of its biodegradability and biocompatibility.7 Due 
to the hydrophobic nature of PLGA molecules, hydrophobic 
drugs, including most anticancer agents, can be easily loaded 
into PLGA nanoparticles.8 Surface treatments of PLGA nano-
particles are carried out using different functional groups for 
various purposes, such as targeted drug delivery and a long 
blood circulation time. Most often, carboxylic acid or amine 
groups are attached to the nanoparticle surfaces and used for 
further conjugation purposes. For this reason, the technique 
usually employed to conjugate trastuzumab to nanoparticles 
is amine coupling involving carboxyl activation via the highly 
water-soluble sulfo-N-hydroxysuccinimide (NHS) ester. 
Eghtedari et al have reported a novel technique to functional-
ize gold nanorods, enabling in vivo targeting of breast cancer 
tumors by attachment of trastuzumab and polyethylene glycol 
(PEG) on the surfaces of nanoparticles.9
In another study, PLGA immunonanoparticles conjugated 
with monoclonal antibodies were prepared by a double 
emulsion and adsorption technique using 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) as a reversible 
crosslinker. The immunonanoparticles were internalized 
directly into an MCF-10A neoT cell line, indicating that the 
system can be used to build up targeted and stable carrier 
systems.10
The length of the crosslinker is very important, because 
the accessibility of the ligand is directly related to the length 
of the crosslinker, and the use of an extended spacer arm can 
greatly reduce steric hindrance. In many cases, short dis-
tances between the targeting moieties and the surface of the 
nanoparticles lead to poor receptor binding affinities and thus 
poor biological effects.11 To resolve this problem, we used 
PEG-maleimide (PEG-MAL) as a linker between PLGA and 
the antibody. PEG-MAL is more reactive with thiol groups. 
Alternatively, trastuzumab could be thiolated with suitable 
agents, such as 2-iminothiolane, which will conjugate to the 
free amine groups of the antibody.11,12
In our previous studies, we investigated different 
approaches for the delivery of docetaxel, a leading che-
motherapeutic drug for breast carcinoma, ovarian cancer, 
head and neck, and lung cancer, using nanoparticulate 
systems.13–17 In this study, we report on the preparation 
and characterization of trastuzumab-decorated pegylated 
PGLA nanoparticles as a targeted delivery system for 
  docetaxel. The quantity of monoclonal antibodies attached 
to the surface of the nanoparticles was characterized. 
Their ability to target and enter antigen-rich BT-474 cells 
was studied and compared with Calu-6 cells as a negative 
control.
Materials and methods
Materials
Docetaxel was obtained from Cipla (Mumbai, India). PLGA 
(lactide:glycolide, 50:50; Resomer RG 504H, molecular 
weight 48,000) was purchased from Boeringer Ingelheim 
(Ingelheim, Germany). Polyvinyl alcohol (molecular 
weight 22,000) and bifunctional NH2-PEG-OH (average 
molecular weight 5000) were purchased from Sigma-Aldrich 
(St Louis, MO). EDC, NHS, 2-iminothiolane (Traut’s 
reagent), 5,5′-dithio-bis(2-nitro-benzoic acid (Ellman’s 
reagent), hydroxylamine hydrochloride, and cysteine hydro-
chloride were obtained from Fluka (Buchs, Switzerland). 
4-Aminobenzoic acid p-aminobenzoic acid and 3-(4,5-
dimethylthiazol-2-yl)-(2,5-diphenyl tetrazolium bromide)
(MTT) was purchased from Sigma-Aldrich.
cell culture
The breast cancer cell lines, BT-474 and SKBR3, and a 
Calu-6 lung cell line (American Type Culture Collection) 
were obtained from the Pasteur Institute (Tehran, Iran). The 
cell lines were cultivated in RPMI-1640 medium supple-
mented with 10% fetal bovine serum and 1% penicillin-
streptomycin at 37°C in a humidified incubator with 5% CO2. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1905
Targeted docetaxel immunonanocarriers
The cells were maintained in an exponential growth phase 
by periodic subcultivation.
synthesis of PLgA-Peg
Hydrixylate-functionalized copolymer PLGA-PEG was 
synthesized by conjugation of OH-PEG-NH2 to PLGA-
COOH. NHS (135 mg, 1.1 mmol) in the presence of EDC 
(230 mg, 1.2 mmol) was added to a stirred solution of 
PLGA-COOH (5 g, 0.28 mmol) in methylene chloride 
(10 mL). The mixture was stirred for 3 hours at 25°C. 
PLGA-NHS was precipitated with ethyl ether (5 mL) and 
repeatedly washed in an ice-cold mixture of ethyl ether and 
methanol to remove the residual NHS. After drying under 
vacuum, PLGA-NHS (1 g, 0.059 mmol) was dissolved in 
chloroform (4 mL) followed by addition of NH2-PEG-OH 
(250 mg, 0.074 mmol) and N,N-diisopropylethylamine 
(28 mg, 0.22 mmol). The copolymer was precipitated with 
cold methanol after 12 hours and washed with the same 
solvent (35 mL) to remove unreacted PEG. The resulting 
PLGA-PEG block copolymer was dried under vacuum and 
used for nanoparticle preparation without further treatment. 
The following are the main nuclear magnetic resonance 
(NMR) peaks of the sample:
1H-NMR (CDCl3 at 300 Hz) d 5.2 (m, (OCH(CH3)
C(O)OCH2C(O)n-(CH2CH2O)m), 4.8 (m, (OCH(CH3)C(O)
OCH2C(O)n-(CH2CH2O)m), 3.7 (s, (OCH(CH3)C(O)OCH2C(O)
n-(CH2CH2O)m), 1.6 (d, (OCH(CH3)C(O)OCH2C(O))
n-(CH2CH2O)m.
synthesis of p-maleimidobenzoic acid
The benzoic acid derivative was synthesized according to the 
procedure described by Yushika et al. 4-Aminobenzoic acid 
(4.26 g, 31 mmol) was suspended in 30 mL of acetone by 
addition of 5 mL of methanol. A solution of maleic anhydride 
(3.66 g, 37 mmol) in 10 mL of acetone was added dropwise 
and the resulting precipitate was stirred for 20 minutes. The 
material was suction-filtered, washed with acetone, and 
vacuum-dried to yield a yellow powder (6.36 g). The resi-
due was dissolved in acetic anhydride (13 mL), treated with 
sodium acetate (1.08 g), and refluxed at 50°C for 2 hours. The 
volatiles were then removed under reduced pressure, and the 
residue was taken up in 150 mL of water and heated at 70°C 
for 2.5 hours. The resulting white precipitate was suction-
filtered, washed with water, and vacuum-dried overnight to 
yield P-maleimidobenzoic acid (4.7 g, 70%). The following 
are the NMR main peaks of the sample:
1H-NMR (CDCl3 at 300 Hz): d 10.0–8.5 (br s, 1 H, 
CO2H), 7.95 (d, J = 9 Hz, 2 H, Ar-H ortho to maleimide), 7.32 
(d, J = 9 Hz, 2 H, Ar-H ortho to carboxylic acid), 6.8 (s, 2 H, 
maleimide vinyl).
synthesis of p-maleimidobenzoy1 azide
P-maleimidobenzoic acid (215 mg, 1 mmol), sodium azide 
(651 mg, 1 mmol), and excess N-hydroxysuccinimide 
(123 mg, 1 mmol) were refluxed in 50 mL acetonitrile for 
2 hours in the presence of EDC (230 mg, 1.2 mmol). The 
solvent was removed under reduced pressure. The following 
are the NMR main peaks of the sample:
lH-NMR (CDCl3 at 300 Hz): 6 8.0 (d, J = 8 Hz, 2 H, Ar-H 
ortho to maleimide), 7.45 (d, J = 8 Hz, 2 H, Ar-H ortho to 
acyl azide), 6.75 (8, 2 H, maleimide vinyl).
synthesis of Peg-PLgA with maleimide 
functional group
Dry toluene 150 mL was added to the residue and refluxed 
under nitrogen for 1 hour and 20 minutes. Toluene was 
decanted, and the copolymer of PLGA-PEG was added to 
it and stirred at room temperature overnight. The yielded 
polymer was filtered, washed with water, and dried. The 
following are the NMR main peaks of the sample:
1H-NMR (CDCl3 at 300 Hz) d 5.2 (m, ((OCH(CH3)
C(O)OCH2C(O))n-(CH2CH2O)m), 4.8 (m, ((OCH(CH3)
C(O)OCH2C(O))n-(CH2CH2O)m), 3.7 (s, ((OCH(CH3)
C(O)OCH2C(O))n-(CH2CH2O)m), 1.6(d, ((OCH(CH3)C(O)
OCH2C(O))n-(CH2CH2O)m), 6 8.0 (d, J = 8 Hz, 2 H, Ar-H 
ortho to maleimide), 7.45 (d, J = 8 Hz, 2 H, Ar-H ortho to 
PLGA-PEG), 6.75 (8, 2 H, maleimide vinyl).
Preparation of docetaxel-loaded 
pegylated PLgA nanoparticles
PLGA-PEG copolymer nanoparticles loaded with docetaxel 
were prepared using a nanoprecipitation method. Briefly, 
copolymer and the drug were dissolved in acetone. This 
organic phase was emulsified with an aqueous solution of 
polyvinyl alcohol (0.5% w/v) by sonication using a probe 
sonicator (Cole Parmer) at amplitude 5 for 60 seconds. 
Nanoparticles were formed immediately, and gently stirred 
at room temperature for 5 hours to evaporate the organic 
solvent. The resulting nanoparticle suspension was then 
ultracentrifuged at 15,000 rpm for 20 minutes. After cen-
trifugation, the nanoparticle precipitate was washed using 
the same volume of distilled water as the supernatant, and 
again centrifuged at 15,000 rpm for 15 minutes. The wash-
ing process was repeated three times in order to remove 
the adsorbed drugs. The washed nanoparticles were then International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  freeze-dried using the FreeZone system (Labconco, FreeZone 
Plus 6) for 48 hours.
Thiolation of trastuzumab: quantification 
of thiol groups
Trastuzumab was thiolated with a 50-fold molar excess of 
2-iminothiolane for 2 hours and purified as described earlier, 
ie, an aliquot (1.0 mL) of trastuzumab solution at a concentra-
tion of 1 mg/mL in phosphate buffer pH 8.0 was thiolated 
with 40.2 mL of 2-iminothiolane solution for 2 hours. The 
antibody was purified by Microcons 100,000 microconcen-
trators (Amicon, Beverly, MA).
The concentration of antibody solution obtained from 
the purification step was about 1.1 mg/mL. Aliquots 
(250.0 mL) of concentrated trastuzumab solution were 
incubated with 6.25 mL of Ellman’s reagent (8.0 mg in 
2.0 mL phosphate buffer, pH 8.0) for 15 minutes at 25°C. 
Afterwards, the samples were measured photometrically in 
UVette (  Eppendorf AG, Hamburg, Germany) at 412 nm. 
The number of thiol groups introduced was calculated rela-
tive to L-cysteine standard solutions that were treated in the 
same manner. The concentration of antibody calculated by a 
spectrophotometric method (λ = 280 nm, Hewlett Packard, 
Model 8453, Germany) was used, assuming an extinction 
coefficient of 1.4 M−1 cm−1.
Immunoreactivity of thiolated 
trastuzumab
To examine the binding affinity and specificity of thiolated 
trastuzumab, 1 × 104 HER2-overexpressing breast cancer 
cells (BT-474) and negative cells (Calu-6) were incubated 
with 1 µL of 2 mg/mL trastuzumab as a control and thio-
lated trastuzumab in 0.5 mL phosphate-buffered saline for 
1 hour at 4°C. The cells were then pelleted by centrifuga-
tion, suspended in 0.5 mL phosphate-buffered saline, and 
incubated with fluorescein isothiocyanate (FITC)-labeled 
sheep antihuman immunoglobulin as a secondary antibody 
for 1 hour. Thereafter, the cells were washed and analyzed 
using a FACScan flow cytometer (Becton Dickinson, San 
Jose, CA).
covalent coupling of thiolated 
trastuzumab to PLgA nanoparticles
For the coupling reaction, an aliquot (500.0 µL) of sulf-
hydryl-reactive nanoparticle suspension (about 10 mg of 
nanoparticles) was incubated with 500.0 µL of thiolated 
trastuzumab (about 250 µg) for at least 12 hours at 20°C 
under constant shaking at 600 rpm. The samples were 
purified from the unreacted antibody by three cycles of 
  centrifugation (18,000 × rpm, 15 minutes, 4°C). The amount 
of trastuzumab conjugated to a nanoparticle was determined 
indirectly by measuring uncoupled monoclonal antibodies in 
the supernatant after the centrifugation step. A spectrophoto-
metric method (λ = 280 nm, Hewlett Packard, Model 8453, 
Germany) was used, assuming an extinction coefficient of 
1.4 M−1 cm−1. The total amount of trastuzumab bound to the 
nanoparticle surface was calculated as the difference between 
the total amount of antibody obtained after thiolation and 
purification and the amount of antibody determined in the 
supernatant obtained after the conjugation step. The follow-
ing equation was used to calculate the number of monoclonal 
antibodies molecules conjugated on the surface of a single 
nanoparticle:
  na N = 
 

 
d
r
4
3
3 π
 
(1)
where n is the number of trastuzumab molecules per nano-
particle, a is the mol of monoclonal antibodies per g PLGA, 
d is the density of nanoparticles (estimated to be 1.5 g/cm3 
based on the polymer density), r is the mean radius of nano-
particles, and N is Avogadro’s number.18
Determination of monoclonal antibodies 
on the surface of nanoparticles
A secondary antibody, FITC-labeled sheep antihuman immu-
noglobulin, was used to identify the presence of monoclonal 
antibodies on the surface of the nanoparticles. Monoclonal 
antibody-modified nanoparticles were treated with 0.5 µL of 
labeled sheep antihuman immunoglobulin at room tempera-
ture for 2 hours. The volume ratio between the solution of 
secondary monoclonal antibodies and dispersion of immu-
nonanocarriers was 1:1000. Samples were centrifuged at 
13,200 rpm for 15 minutes and washed twice with 1 mL of 
phosphate-buffered saline to eliminate the excess secondary 
monoclonal antibody. After a final washing, the sediment was 
redispersed in phosphate-buffered saline at pH 7.4, and the 
fluorescence intensity of fluorescent dye (fluorescein, λ ex 
494 nm and λ em 525 nm) was measured using a microplate 
reader (Safire2™, Tecan, Switzerland). The fluorescence 
intensity was compared with that of the noncoated nanopar-
ticles, FITC-labeled sheep antihuman immunoglobulin, and 
phosphate-buffered saline at pH 7.4 as the median.
size and zeta potential measurements
The mean size of the PLGA nanoparticles and targeted 
  nanoparticles was determined by laser light scattering International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(Malvern Zetasizer ZS, Worcestershire, UK). Each freeze-
dried sample (100 µg) was diluted with water (10 mL), 
filtered to avoid multiscattering phenomena, and placed in 
a quartz cuvette. Size analysis of each sample consisted of 
13 measurements, and the result was expressed as mean 
size ± standard deviation. Zeta potential measurements were 
performed on the same samples prepared for size analysis. 
Zeta limits ranged from −120 to 120 mV .
surface morphology
Scanning electron microscopy (SEM, Philips XL 30, Philips, 
The Netherlands) was used to determine the shape and sur-
face morphology of the nanoparticles produced. Particles 
were coated with gold under vacuum before scanning electron 
microscopy.
Drug loading efficiency
Lyophilized nanoparticles (2.5 mg) were dissolved in 1 mL 
of acetonitrile and shaken lightly followed by sonication 
for 6 minutes. Thereafter, 2 mL of methanol was added to 
precipitate the polymer. The sample was filtered and the drug 
quantity in the filtrant was determined by high-pressure liquid 
chromatography. Drug loading was determined as the relative 
amount of drug content of nanoparticles to the whole weight 
of the nanoparticles.
In vitro docetaxel release
The docetaxel release profile at pH 7.4 in phosphate-
buffered saline and at pH 5.5 in acetate buffer was studied. 
5   milligrams of freeze-dried docetaxel-loaded nanoparticles 
was poured into screw-capped tubes and suspended in 10 mL 
of phosphate-buffered saline pH 7.4 or acetate buffer pH 
5.5. The tubes were placed in a water bath maintained at 
37°C ± 0.5°C and shaken at 90 cycles/minute. At fixed 
time intervals, the tubes were taken from the water bath and 
  centrifuged at 21,000 g for 15 minutes. The nanoparticles 
were resuspended in 10 mL of fresh buffer and placed back 
into the water bath to continue the release measurements. An 
aliquot of 9 mL was taken from the supernatant. A volume 
of 1 mL of methanol was added to precipitate any remaining 
PLGA, centrifuged for 15 minutes at 21,000 g, and analyzed 
by high-pressure liquid chromatography. The experiments 
were carried out in triplicate.
high-pressure liquid chromatography
High-pressure liquid chromatography was performed 
at room temperature using a Knauer apparatus model 
K-1001,   WellChrom (Berlin, Germany) equipped with 
a   reversed-phase C18 column (25 cm × 0.46 cm internal 
diameter, pore size 5 µm; Teknokroma, Barcelona, Spain) 
and eluted isocratically with acetonitrile/water (65/35 v/v). 
The flow rate was fixed at 1 mL/min, with ultraviolet detec-
tion at 230 nm. The linear regression coefficient determined 
in the range 0.05–10 µg/mL was 0.9994 (n = 6). The method 
sensitivity was 0.05 µg/mL (signal to noise ratio, 3:1).
cell targeting and internalization  
of immunonanoparticles
Cellular targeting and uptake of trastuzumab and immu-
nonanoparticles were investigated using monocultured 
SKBR3 and BT-474 as HER2-overexpressing cells and 
negative Calu-6 cells. The cells were seeded on chambered 
eight-well coverslips (Nunc, Naperville, IL) at a density 
of 2 × 104 cells per well. The next day, the spent growth 
medium was removed. The cells were incubated with 500 µL 
of 0.5 mg/mL FITC-labeled trastuzumab-modified nanopar-
ticles in serum-free medium, and 500 µL of 5 µg/mL trastu-
zumab in serum-free medium at 37°C for 1 hour. The cells 
were washed three times with cold phosphate-buffered saline 
to remove any nanoparticles not internalized by the cells, and 
were fixed with 4% paraformaldehyde in phosphate-buffered 
saline for 10 minutes. The cells were then washed again 
three times with cold phosphate-buffered saline. Thereafter, 
4,6-diamidino-2-phenylindole (DAPI, Invitrogen) was used 
to counterstain the nuclei of the cells. The cells were then 
washed with phosphate-buffered saline. Finally, the cells 
were imaged using an Olympus IX/81 inverted fluorescence 
microscope (ultraviolet visible) and the images were analyzed 
using CellR Imaging software. Each measurement was per-
formed in triplicate.
Additionally, internalization of FITC-loaded noncoated 
and immunonanoparticles into SKBR3 and Calu-6 cells 
was evaluated using flow cytometry. Cells were placed into 
six well plates and left to attach; 200 µL of fluorescein-
loaded immunonanoparticles or noncoated nanoparticles 
(0.5 mg/mL) were then added to each well and incubated for 
15, 30, 45, and 60 minutes. As a control, cells were grown 
separately in the absence of nanoparticles. Flow cytometry 
was performed on a FACSCalibur (Becton Dickinson Inc, 
Franklin Lakes, NJ).
In vitro cell viability
The in vitro cytotoxicity of the following docetaxel for-
mulations was tested on BT-474 cells using the MTT test: 
NP-DTX-HER, NP-DTX, and free docetaxel. Unloaded 
nanoparticles and IgG isotype monoclonal antibodies were International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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conjugated to the surface of the nanoparticles to act as a 
control for the corresponding anti-HER2 conjugated nano-
particles, and tested to determine the effects of the polymer 
on cell viability.
BT-474 cells were seeded in 96-well plates (Costar, 
Chicago, IL) at the density of 1 × 104 viable cells/well and 
incubated for 24 hours to allow cell attachment. The medium 
was replaced by 100 µL of the formulation at concentrations 
of 1–200 nM for 48 hours. For free docetaxel, a stock solution 
was prepared in dimethyl sulfoxide (1 mg/mL docetaxel). The 
dimethyl sulfoxide concentration in the medium was lower 
than 0.5%, at which level it has no effect on cell   proliferation. 
The diluent for preparing the working solution for free 
docetaxel drug and nanoparticles was RPMI-1640 culture 
medium. At designated time intervals, 20 µL MTT (5 mg/mL 
in phosphate-buffered saline) was added to each well, and the 
culture medium containing MTT solution was removed after 
3–4 hours. The formazan crystals were dissolved in 100 µL 
dimethyl sulfoxide and read at 570 nm by a microplate reader. 
Cell viability was calculated using the following equation:
  Cell viability (%) = (Ints/Intcontrol) × 100  (2)
where Ints is the colorimetric intensity of cells incubated 
with the samples, and Intcontrol is the colorimetric intensity 
of cells incubated with the phosphate-buffered saline only 
(positive control).
statistical analysis
One-way analyses of variance were performed for compari-
son of the results. P values of 0.05 were considered to be 
statistically significant.
Results and discussion
Cancer is among the top causes of morbidity and mortality in 
humans worldwide. Development of new drugs and chemo-
therapy agents has opened up new horizons for the treatment 
of tumors. Optimum concentration of drugs at a tumor site 
is presently only possible at the cost of severe side effects. 
Nanocarriers with tumor-targeting moiety attachments, such as 
epidermal growth factor,19 RGD peptide, folate,20 transferrin,21 
or antibodies and antibody fragments, can maximize tumor-
targeted delivery and limit drug side effects. In this study 
docetaxel-loaded nanoparticles conjugated with the anti-
HER2 monoclonal antibody, trastuzumab, were prepared.
synthesis of PLgA-Peg-MAL
PEG-PLGA with the functional group maleimide was syn-
thesized and characterized. The basic chemical structure of 
PLGA-PEG copolymer was confirmed by 1H-NMR. One of 
the prominent features is a peak at 3.7 ppm, matching the 
methylene groups of PEG. Overlapping doublets at 1.6 ppm 
are attributed to the methyl groups of the D- and L-lactic 
acid repeat units. The multiples at 5.2 ppm and 4.8 ppm cor-
respond to the lactic acid CH and the glycolic acid CH, 
respectively, with the high complexity of the peaks resulting 
from different D-lactic, L-lactic glycolic acid sequences 
in the polymer backbone. Proton signals from phenyl and 
maleimide groups can be also detected. The maleimide group 
located at the end terminal of the hydrophilic PEG block is 
available for surface chemistry on the nanoparticle surface.
Preparation and characterization  
of docetaxel-loaded nanoparticles
At first, docetaxel was encapsulated in the pegylated PLGA 
nanoparticles with maleimide end groups by the nanopre-
cipitation method. The physicochemical characteristics of 
the nanoparticles are summarized in Table 1. The NPs-DTX-
HER nanoparticles were prepared by covalent coupling of 
monoclonal antibodies to the NP-DTX using a two-step 
  reaction. Covalent reactions are a useful method for attach-
ing the ligands irreversibly to nanocarriers, because the 
connection formed is very stable and reproducible. The 
covalent binding between nanoparticles and the ligand must 
not affect the biological activity of the ligand. The amount 
of monoclonal antibody conjugated is approximately 195 
anti-HER2 per nanoparticle.
Immunoreactivity of thiolated 
trastuzumab
Thiolation of the antibody is an essential step for preparation 
of immunonanoparticles. Sulfhydryl groups were introduced 
into the monoclonal antibody molecule to provide a reac-
tive site for the conjugation with maleimide groups onto 
the nanoparticle surface. Sulfhydryl groups were attached 
to trastuzumab molecules by a ring opening reaction of the 
primary amino groups of trastuzumab using 2-  iminothiolane. 
Table 1 Physicochemical characteristics of poly lactic-co-glycolic 
acid nanoparticles and targeted nanoparticles (n = 3)
Sample Mean hydrodynamic  
diameter ± SD (nm)
PDI ± SD Zeta  
potential ±   
SD (mV)
DTX NPs 181 ± 3.5 0.265 ± 0.09  − 2.6 ± 0.34
DTX- 
targeted NPs
254 ± 16.4 0.33 ± 0.06 −11.5 ± 1.4
Abbreviations: DTX, docetaxel; NP, nanoparticles; PDI, polydispersity index;   
sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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These groups are at risk of oxidative disulfide bridge 
  formation, leading to dimers or even higher oligomers of 
trastuzumab. These byproducts could affect biological activ-
ity so are undesirable. Steinhauser et al evaluated different 
thiolation conditions and determined the degree of antibody 
dimerization. They analyzed the thiolated antibody by size 
exclusion chromatography and identified the best thiolation 
procedure for the preparation of trastuzumab-conjugated 
nanoparticles.22 We used their optimized conditions to 
produce thiolated trastuzumab and studied the immunore-
activity of thiolated anti-HER2 antibodies on BT-474 cells 
using FITC-labeled monoclonal antibodies. There was no 
significant difference in activity between native and thiolated 
anti-HER2 monoclonal antibodies.
Determination of monoclonal antibodies 
on the surface of nanoparticles
In order to verify the covalent linkage of the antibody to 
nanoparticles, an FITC-labeled sheep antihuman antibody 
coupling to anti-HER2 monoclonal antibody experiment 
were performed using increasing fluorescent intensity of the 
antibody-modified nanoparticles compared with unmodi-
fied nanoparticles (Table 2). The increase in fluorescent 
intensity of the antibody-modified nanoparticles indicated 
that the monoclonal antibody was covalently attached to the 
surface of the nanoparticles. Therefore, the concentration of 
FITC-labeled sheep antihuman antibody on the nanoparticle 
surface was increased.
characterization of immunonanoparticles
The most important characteristic of nanoparticle systems is 
their size and size distribution. The biodistribution, toxicity, 
and targeting ability of these systems is determined by their 
size. Pore sizes in tumor microvasculature vary between 
100 nm and 780 nm.22 Many studies have recognized the suit-
able size of these carriers for extravasation and accumulation 
in solid tumors below 400 nm.23 As shown in Table 1, the 
nontargeted nanoparticles had a size of 181 ± 3.5 nm, whereas 
the monoclonal antibody-targeted nanoparticles were larger 
at 254 ± 16.4 nm. Conjugation may be a reason for the larger 
size of the targeted nanoparticles. Several steps of the cen-
trifugation and freeze-drying process may be another reason 
for the larger size of the targeted   nanoparticles.24 Scanning 
electron microscopy showed that both the nanoparticles and 
targeted nanoparticles were spherical and rather homoge-
neous in size (Figure 1).
For nanoparticles and monoclonal antibody-targeted 
nanoparticles, the zeta potential was −2.63 ± 0.34 mV 
and −11.5 ± 1.4 mV , respectively. This result shows that the 
mean zeta potential of the nanoparticles is lower than that 
previously reported for empty PLGA nanoparticles (−25 mV), 
indicating that the maleimide end groups of the polymer are 
located on the surface of the nanoparticle. After coupling of 
the anti-HER2 monoclonal antibodies to the nanoparticles, 
containing several ion groups, the negative value of the zeta 
potential is increased, suggesting that conjugation of mono-
clonal antibodies to the nanoparticles leads to an increase in 
the negative surface charge of the targeted nanoparticles.
In vitro docetaxel release
The profile in vitro release of docetaxel from nanoparticles 
in the acetate buffer (pH 5.5) and phosphate-buffered saline 
(pH 7.4) within 200 hours is depicted in Figure 2. During 
the first day of release, an early burst release greater than 
60% was detected. A slow and steady release of docetaxel 
was observed after the burst release. The burst release may 
be due to the release of docetaxel loaded on the surface or 
just beneath the surface of the nanoparticles. The sustained 
docetaxel release following the initial burst release may be 
the result of diffusion of docetaxel through the polymeric 
matrix.25 The main objective of using nanocarriers as drug 
delivery systems against cancer cells is targeted delivery 
rather than sustained delivery. Therefore, the fast drug release 
from these immunonanocarriers is not a negative feature.
Table  2  Fluorescent  intensity  of  nanoparticles,  targeted  nano-
particles,  phosphate-buffered  saline  as  solution,  and  sheep 
antihu  man antibody conjugated with fluorescein-5-isothiocyanate
Fluorescent intensity
Phosphate-buffered saline 4430 ± 5.2
Nanoparticle without mAb 6006 ± 3.4
Immunonanoparticle 70,528 ± 5.2
sheep antihuman antibody 8696 ± 5.8
Note: Data are represented as mean ± standard deviation (n = 3).
Abbreviation: mAb, monoclonal antibody.
NanoparticlesT argeted nanoparticles
Figure 1 scanning electron microscopic image of (A) poly lactic-co-glycolic acid 
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cell targeting and internalization  
of immunonanoparticles
Cellular uptake of immunonanocarriers was studied in three 
different cell lines via confocal microscopy, and compared with 
pure trastuzumab. As shown in Figure 3, SKBR3 and BT-474 
cell lines with overexpression of HER2 antigen showed higher 
uptake of the immunonanocarriers (Figure 3D and F, green 
regions in the cytosol and blue regions in the nucleus). These 
results are in line with other studies demonstrating specific 
binding and internalization of anti-HER2 nanoparticulate drug 
delivery systems, such as immunoliposomes or immunonano-
particles.18 However, fewer nanoparticles were internalized by 
HER2-negative Calu-6 cells (Figure 3A).
The results of flow cytometry also showed that uptake of 
the FITC-loaded immunonanoparticles by SKBR3 was higher 
than that by Calu-6 cells. Higher uptake of targeted nanoparti-
cles by SKBR3 cells was in agreement with a previous study.26 
These results also suggest that immunonanoparticles may 
be taken up more rapidly than nontargeted nanoparticles.
Percentage cell gating of SKBR3 was significantly higher 
than for Calu-6 for targeted nanoparticles (Figure 4A) con-
firming that the immunonanoparticles may attach to and be 
internalized by those cells with high expression of antigens 
(SKBR3 cells) compared with cells without expression of 
antigens (Calu-6). As shown in Figure 4B, for nontargeted 
nanoparticles cellular uptake by both cell lines is the same.
In vitro cellular cytotoxicity assay
A series of in vitro cytotoxicity assays was performed to 
evaluate the anticancer potential of docetaxel-encapsulated 
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Figure 2 In vitro docetaxel release profiles from docetaxel-loaded nanoparticles 
in  phosphate-buffered  solution  (ph  =  7.4,  37°c).  Data  are  represented  as 
mean ± standard deviation (n = 3).
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Figure 3 (A) Fluorescence microscope image of her2-overexpressing sKBr3 and 
BT-474 cells and (B) her2-negative calu-6 cells, incubated with FITc-conjugated 
trastuzumab  and  docetaxel-PLgA  nanoparticles  coated  with  FITc-conjugated 
monoclonal antibody after 1 hour of incubation.
Abbreviations: HER2, human epidermal growth factor receptor 2; FITC, fluorescein 
isothiocyanate; PLgA, poly lactic-co-glycolic acid.
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targeted nanoparticles using BT-474 (HER2-positive) cells 
in comparison with that of free docetaxel. Nontargeted and 
trastuzumab-conjugated nanoparticles with no drug loading 
were also tested to determine the effects of polymerization and 
conjugation on cell viability. Statistical analysis showed that 
the unloaded nanoparticles did not influence cell viability. As 
shown in Figure 5, docetaxel-loaded nanoparticles were highly 
cytotoxic to BT-474 cells which express the HER2 antigen on 
their surface. They were also more toxic than free docetaxel in 
the BT-474 cells, indicating the potential of these nanoparticles 
to treat human breast cancer. The greater efficiency of the 
immunonanoparticles can be explained by their specific interac-
tion with HER2 antigens on the surface of BT-474 cells.18
Conclusion
In this study, trastuzumab-decorated pegylated PLGA nano-
particles with suitable characterization were successfully 
prepared for targeted delivery of docetaxel. Their size, size 
distribution, surface charge, surface morphology, drug load-
ing, and in vitro drug release were characterized. In vitro 
cytotoxicity studies of docetaxel-loaded immunonanocarriers 
showed greater cytotoxicity effects against BT-474 HER2-
positive breast cancer cells. These results suggest that mono-
clonal antibody-targeted nanoparticles are potentially useful 
as targeting delivery systems for chemotherapeutic agents.
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